Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #6

    Link virker ikke. Kan ses på ØU

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #7

      Gode afkast i pharmasektoren.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #8

        Zealand Novo og Genmab.

        1 Reply Last reply
        0
        • H Offline
          H Offline
          Hen
          wrote on sidst redigeret af
          #9

          Link til ØU: https://ugebrev.dk/flashnews/aarsstatus-for-danske-aktier-2022-kun-43-plusser-blandt-163-danske-aktier-se-hvilke/

          1 Reply Last reply
          0
          • P Offline
            P Offline
            peter12
            wrote on sidst redigeret af
            #10

            Interessant artikel om CAR-T contra Bispecific Antibodies, Godt nytår ! https://themmrf.org/2022/12/28/answers-to-faqs-from-our-12-20-22-expert-session-on-myeloma-highlights-from-the-ash-2022-meeting/

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #11

              Godmorgen 🙂

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Stroka
                wrote on sidst redigeret af
                #12

                God morgen 🙂

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #13

                  God morgen 🙂

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #14

                    Genmab-topchef: Tre kræftmidler er på vej mod væsentlige milepæle i 2023 - https://medwatch.dk/Medicinal___Biotek/article14766808.ece - godt nytår 🙂

                    1 Reply Last reply
                    0
                    • Legolas23L Offline
                      Legolas23L Offline
                      Legolas23
                      wrote on sidst redigeret af
                      #15

                      En lille nyhed, som ikke er nævnt fra før nytår. FDA godkender kræftmiddel fra Roche https://medwatch.dk/Medicinal___Biotek/article14761309.ece

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #16

                        Link Preview Image
                        Eyes have been opened to the Genmab-Biontech collaboration, says CEO

                        The companies’ partnership is moving into a ”more promising phase,” and investors have begun to pay attention, says Genmab CEO Jan van de Winkel while championing the collaborative approach.

                        favicon

                        (medwatch.com)

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #17

                          Lidt mere Genmab i Medwatch

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #18

                            Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference https://www.proinvestor.com/investornyt/922129/genmab-to-present-at-the-41st-annual-jp-morgan-healthcare-conference

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #19

                              Mon Genmabs GEN1042 kan følge i Alligators fodspor:

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #20

                                Just a moment...

                                favicon

                                (firstwordpharma.com)

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #21

                                  Det skulle man jo mene. Så vidt jeg kan se er mitazalimab ikke bispecifikke. Men targetterer alene cd40 på dendritceller og derigennem T-cellerne. Gen1042 targetterer også 4-1bb og derigennem mere direkte T-cellerne - så vidt jeg har forstået.

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #22

                                    Nu kører 1042 i kombi med en pd-l1 blokker, og vi ved jo ikke hvad der ville komme ud af også at kombinere den med kemo.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #23

                                      Og så kører 1042 jo nu også i flere kombier med kemo, og har en arm med bugspytkirtlen også. https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #24

                                        Tirsdagens danske avisuddrag med Vestas, elbiler og kapitalfonde https://www.proinvestor.com/investornyt/922276/tirsdagens-danske-avisuddrag-med-vestas-elbiler-og-kapitalfonde

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #25

                                          Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.globenewswire.com/news-release/2023/01/03/2581869/0/en/Janssen-Submits-Marketing-Authorisation-Application-to-the-European-Medicines-Agency-Seeking-Approval-of-Talquetamab-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multi.html

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper